I

n the latest effort to mitigate the cost of hepatitis C drugs in a poor country, Doctors Without Borders is challenging a patent application that Gilead Sciences filed in China for its newest treatment.

The nonprofit organization hopes to prevent the drug maker from winning patent protection for Epclusa, which is the first pill to treat all six major subtypes of the liver disease and costs nearly $75,000 in the U.S. for a 12- week regimen, before any rebates or discounts. Doctors Without Borders argued the patents Gilead is seeking are not warranted under Chinese law.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • “Doctors Without Borders argued the patents Gilead is seeking are not warranted under Chinese law”. What ? “Doctors Without Borders” wants to destroy Gilead? A firm that invests in research must have profit and be able to use part of it to develop new and better drugs.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy